Results 21 to 30 of about 415,260 (411)
Boosting leukemia-specific T cell responses in patients following stem cell transplantation [PDF]
, 2014 Whole tumor cell-based vaccines administered within the first 2 to 3 months after allogeneic stem cell transplantation stand out as a promising approach to enhance graft-vs.-leukemia responses. Herein, the implications of this finding for the development
Burkhardt, Ute E, Wu, Catherine J
core +1 more source
Haematologica, 2016 Improvement of graft-versus-host disease prophylaxis remains an important goal in allogeneic hematopoietic stem cell transplantation. Based on reports of possibly preferential properties of sirolimus, we compared the standard regimen of cyclosporine and ...
Johan Törlén +8 more
doaj +1 more source
Iraqi Journal of Hematology, 2022 BACKGROUND: In allogeneic stem cell transplantation, donor and recipient HLA tissue compatibility is essential for the success of stem cell transplantation. HLA tissue compatibility percentage is the most important parameter that increases the success of
Ahmet Kaya +8 more
doaj +1 more source
A proof-of-concept clinical trial using mesenchymal stem cells for the treatment of corneal epithelial stem cell deficiency [PDF]
, 2019 Producción CientíficaOcular stem cell transplantation derived from either autologous or allogeneic donor corneoscleral junction is a functional cell therapy to manage extensive and/or severe limbal stem cell deficiencies that lead to corneal epithelial ...
Alberca Zaballos, Mercedes +9 more
core +2 more sources
Allogeneic stem cell transplantation for neuroblastoma [PDF]
The Korean Journal of Hematology, 2012 Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although the prognosis of lowand intermediate-risk NB with conventional treatment modalities is excellent, the prognosis of high-risk NB with conventional treatment alone is very poor. The current standard treatment for high-risk NB consists of induction treatment (conventional
openaire +3 more sources
Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.
Blood, 2014 Because the outcome of allogeneic hematopoietic cell transplantation (HCT) is predominantly influenced by disease type and status, it is essential to be able to stratify patients undergoing HCT by disease risk.
P. Armand +12 more
semanticscholar +1 more source
To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission [PDF]
, 2022 Dear Editor, Acute myeloid leukemia is the most common sub-type of acute leukemia in adulthood [1]. It has a detrimental prognosis with conventional combination chemotherapy, mainly with anthracyclines and cytarabine. Allogeneic stem cell transplantation
Balık Aydın, Berrin +5 more
core +1 more source
International Journal of Molecular Sciences, 2019 Acute myeloid leukemia (AML) is a phenotypically and prognostically heterogeneous hematopoietic stem cell disease that may be cured in eligible patients with intensive chemotherapy and/or allogeneic stem cell transplantation (allo-SCT).
C. Rautenberg +4 more
semanticscholar +1 more source
Regulatory T Cells in Allogeneic Stem Cell Transplantation
Clinical and Developmental Immunology, 2013 Growing evidence suggests that cellular adoptive immunotherapy is becoming an attractive though challenging approach in regulating tumor immunity and alloresponses in clinical transplantation. Naturally arising CD4+CD25+Foxp3+ regulatory T cells (Treg) have emerged as a key component in this regard.
Maria Michael +2 more
openaire +4 more sources
Journal of Immunology Research, 2016 Background. Graft-versus-host disease (GVHD) is a serious complication after allogeneic hematopoietic stem cell transplantation (HSCT). We designed a functional assay for assessment of individual risk for acute GVHD. Study Design and Methods.
Darius Sairafi +4 more
doaj +1 more source